Why Eli Lilly Stock's Big Jump Last Week Could Be Just the Beginning of Another Huge Run

For a while, it seemed the streak was over for Eli Lilly (NYSE: LLY). Shares of the big drugmaker skyrocketed nearly 160% between early 2023 and mid-July of this year. However, Lilly's stock plunged almost 19% afterward -- until last week.On Aug. 8, Lilly reported stellar second-quarter results and the pharma stock quickly soared more than 15%. Here's why Lilly's big jump last week could be just the beginning of another huge run.Recent optimism around the stock is largely due to robust sales for three products: Mounjaro, Zepbound, and Verzenio. While sales for blockbuster breast cancer drug Verzenio vaulted 44% higher in the reported quarter, investors were even more excited about the results for Mounjaro and Zepbound, used to treat diabetes and promote weight loss.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool